ADVENT On Air | Getting to Grips With Atopic Hand and Foot Dermatitis: What Is It, and What Does It Mean for Patients?
Dermatology
This podcast episode looks at the epidemiology, clinical presentation and classification of atopic dermatitis of the hand and feet and the impact it has on patients' qualityoflife.
This static infographic covers the clinical presentations, diagnostic challenges, and disease burden of bullous pemphigoid (BP), a chronic relapsing autoimmune skin disease. Review the steps of diagnosis, which include clinical assessment and laboratory work. Explore comorbidities associated with BP and how they impact patient qualityoflife.
ERS 2024 | Living With COPD: Linking Inflammation with Patient Burden
Pulmonology
Professor Henrik Watz explores the complex relationship between inflammation and COPD, highlighting its impact on patients' health and overall qualityoflife.
The Impact of Skin Fibrosis in Patients with Prurigo Nodularis
Dermatology
An animated infographic exploring the patient burden and pathophysiology of skin fibrosis in prurigo nodularis, specifically detailing how fibrotic pathways are driven and the key molecules involved.
Can Emerging Treatments Help Address Individual PN Patient Burden?
Dermatology
Prof. Sonja Ständer emphasizes the high patient burden of PN, and how this is influenced by patient needs and comorbidities. She discusses how emerging treatments are reducing patient burden.
Current Treatment Landscape and Emerging Therapies
Dermatology
Dr. Lawrence F. Eichenfield reviews the evolving therapeutic landscape for children with AD, considering clinically relevant data supporting the use of advanced systemic therapies. This video was recorded at the EADV 2023 annual meeting during the ‘New Horizons in Children With Atopic Dermatitis: Emerging Evidence in Disease Management’ presentation.
ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.
For healthcare professionals in Algeria: Please read the additional Terms of Use.
Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.